Related Experiment Videos
Apolipoprotein E phenotypes in hemodialysis patients.
1Department of Clinical and Laboratory Medicine, Faculty of Medicine, Fukui Medical University, Japan.
Kidney International. Supplement
|July 21, 1999
Summary
Apolipoprotein E polymorphism affects cholesterol in dialysis patients but doesn't significantly increase atherosclerotic complications. Age and diabetes are key risk factors for vascular disease in hemodialysis patients.
Area of Science:
- Cardiovascular Science
- Genetics
- Nephrology
Background:
- Apolipoprotein E (apo E) polymorphism influences lipid metabolism and atherosclerosis risk in the general population.
- Hemodialysis (HD) patients may experience altered cholesterol levels and increased susceptibility to atherosclerotic vascular disease due to apo E polymorphism.
Purpose of the Study:
- To investigate the association between apo E phenotypes and serum lipid profiles in hemodialysis patients.
- To determine if apo E polymorphism is a risk factor for atherosclerotic vascular disease in HD patients.
Main Methods:
- Determined apo E phenotypes in 493 HD patients and 422 controls.
- Assessed vascular risk profiles and measured postprandial serum lipid and apo levels in dialysis patients.
Main Results:
- Similar apo E phenotype distribution was observed between HD patients and controls.
- Patients with apo E3/4 phenotype exhibited lower high-density lipoprotein cholesterol and higher low-density lipoprotein cholesterol (LDL-C) and atherogenic index compared to apo E2/3.
- Age and diabetes mellitus, not apo E phenotypes, were identified as independent risk factors for vascular disease.
Conclusions:
- Apo E polymorphism modulates cholesterol metabolism in hemodialysis patients.
- Apo E phenotypes showed limited association with the prevalence of atherosclerotic complications in this patient group.